Navigation Links
ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
Date:4/8/2008

Long-term arrangement between two leading non-profit research institutes designed to validate drug targets for the fatal neurodegenerative disease that affects 30,000 Americans

CAMBRIDGE, Mass., April 8, 2008 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) today announced it has entered into an agreement with the Allen Institute for Brain Science in Seattle, Wash. for in situ hybridization (ISH) services using diseased tissues from a preclinical animal model of amyotrophic lateral sclerosis -- ALS, or Lou Gehrig's disease. ALS is a progressive and fatal neurodegenerative disease with no known cause or cure. Under the terms of the agreement, the Allen Institute will perform ISH for genes, in the spinal cord, identified by ALS TDI researchers as being associated with the disease's progression. The aim of this work is to identify cells that are associated with changes in gene expression so that treatments can be directed towards those cells specifically.

"The ongoing data mining efforts at the ALS TDI are identifying hundreds of therapeutic targets that need to be evaluated in vivo. Identification of cells to be targeted by treatments is a crucial step in therapeutic development," said Steven Perrin, Ph.D., Chief Scientific Officer of ALS TDI. "The publication of the Allen Brain Atlas--Mouse Brain project established the Allen Institute as leaders in ISH technologies and capabilities."

At the end of 2007, ALS TDI completed an enormous database of transcriptome information for the SOD1 mouse model, the leading mouse model used internationally by ALS researchers. ALS TDI, a leader in translational research for ALS, has also initiated a similar project and experiment collecting blood samples from people living with the disease today and is expected to expand their collection project and experiments to include other tissues. Through a multi-year funding partnership with the Muscular Dystrophy Association and its Augie's Quest Initiative, ALS TDI expanded its research program to include the largest genomic research program in the history of the disease.

"The goal of the collaboration is to determine exactly where in the spinal cord the genes associated with the progression of ALS are active," said Elaine Jones, Chief Operating Officer of the Allen Institute for Brain Science. "Helping scientists worldwide accelerate their research programs is central to our mission. We're thrilled to be working with ALS TDI to help advance ALS research."

The first samples will arrive from ALS TDI to the Allen Institute in April 2008. A progress report will be provided as part of an annual Leadership Summit and research symposium hosted by ALS TDI in Boston, Mass. on October 20, 2008.

About ALS Therapy Development Institute

The ALS Therapy Development Institute (http://www.als.net), based in Cambridge, Mass., operates the world's largest research and development program focused exclusively on ALS. Its staff of 30 scientists and research technicians work on behalf of ALS patients to discover and advance novel therapeutics for treating and ultimately curing ALS. The non-profit biotechnology institute excels in identifying novel disease targets, discovering compounds that may act against these targets, and screening potential treatments for clinical development. For more information, visit http://www.als.net or call 617.441.7200.

About the Allen Institute for Brain Science

Launched in 2003, the Seattle-based Allen Institute for Brain Science is an independent, 501(c)(3) non-profit medical research organization dedicated to advancing brain research. Started with $100 million in seed money from philanthropist Paul G. Allen, the Institute takes on projects at the leading edge of science--far-reaching projects at the intersection of biology and technology. The resulting data create publicly available resources that fuel discovery for countless other researchers worldwide. The Institute's data and tools are available on the web free of charge at http://www.alleninstitute.org.

About Augie's Quest

Fitness pioneer Augie Nieto started Augie's Quest (http://www.augiesquest.org) in conjunction with MDA's ALS Division. Nieto is co-founder and former president of Life Fitness of Chicago, and chairman of Octane Fitness. He and his wife, Lynne, serve as co-chairpersons of MDA's ALS Division. Nieto received a diagnosis of ALS in March 2005.

About MDA

MDA (http://www.mda.org) is the world's largest provider of ALS services and funder of ALS research. Over the years, it has expended almost $200 million in this effort. It operates 225 neuromuscular disease clinics across the country and 37 ALS-specific research and care centers.

Media Contacts:

ALS TDI

Robert Goldstein

617/441-7295

rgoldstein@als.net

The Fearey Group for the Allen Institute for Brain Science

Aaron Blank

206/343-1543

aaronblank@feareygroup.com


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
8. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
9. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... 2017 , ... An August 3rd article on Reuters covers a new University of ... JAMA (the Journal of the American Medical Association). The study found that a lower percentage ... 30, when compared to patients with lower BMIs. At present, weight loss patients must have ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... In ... They celebrate 30 years in business this year, and they’re marking the milestone ... space to serve their patients. , It stands to reason that, given ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... ... Paul Vitenas, MD, FACS , is honored to announce that he ... the nation’s top physicians, in a variety of specialties. This marks the fourth year ... Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of information on ...
Breaking Medicine News(10 mins):